{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T13:15:26Z","timestamp":1717852526860},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T00:00:00Z","timestamp":1412035200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s11864-014-0314-4","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T16:03:20Z","timestamp":1412006600000},"page":"683-699","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Local and Systemic Therapies for Malignant Pleural Mesothelioma"],"prefix":"10.1007","volume":"15","author":[{"given":"Daniel","family":"Gomez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,30]]},"reference":[{"key":"314_CR1","first-page":"393","volume":"58","author":"Centers for Disease C","year":"2009","unstructured":"Centers for Disease C. Prevention: Malignant mesothelioma mortality--United States, 1999-2005. MMWR Morb Mortal Wkly Rep. 2009;58:393\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"314_CR2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00130404-200311000-00008","volume":"9","author":"A Ahamad","year":"2003","unstructured":"Ahamad A, Stevens CW, Smythe WR, et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J. 2003;9:476\u201384.","journal-title":"Cancer J"},{"key":"314_CR3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"314_CR4","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","volume":"27","author":"LM Krug","year":"2009","unstructured":"Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007\u201313.","journal-title":"J Clin Oncol"},{"key":"314_CR5","doi-asserted-by":"crossref","unstructured":"Rintoul RC, Ritchie AJ, Edwards JG, et al: Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet, 2014. This study showed that video-assisted thoracoscopic partial pleurectomy did not improve survival over talc pleurodesis but may improve quality of life. VAT-PP should be reserved for patients who live beyond 6 months.","DOI":"10.1016\/S0140-6736(14)60418-9"},{"key":"314_CR6","first-page":"367","volume":"9","author":"VW Rusch","year":"1997","unstructured":"Rusch VW. Pleurectomy\/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997;9:367\u201372.","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"314_CR7","doi-asserted-by":"crossref","first-page":"620-6","DOI":"10.1016\/j.jtcvs.2007.10.054","volume":"135","author":"RM Flores","year":"2008","unstructured":"Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620-6\u2013626 e1-3.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"314_CR8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3816\/CLC.2004.n.008","volume":"5","author":"D Martino","year":"2004","unstructured":"Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer. 2004;5:290\u20138.","journal-title":"Clin Lung Cancer"},{"key":"314_CR9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jtcvs.2004.02.021","volume":"128","author":"DJ Sugarbaker","year":"2004","unstructured":"Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138\u201346.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"314_CR10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.thorsurg.2004.06.001","volume":"14","author":"MY Chang","year":"2004","unstructured":"Chang MY, Sugarbaker DJ. Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications. Thorac Surg Clin. 2004;14:523\u201330.","journal-title":"Thorac Surg Clin"},{"key":"314_CR11","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.athoracsur.2007.04.076","volume":"84","author":"DC Rice","year":"2007","unstructured":"Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84:1685\u201392. discussion 1692-3.","journal-title":"Ann Thorac Surg"},{"key":"314_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-5223(19)36577-8","volume":"102","author":"VW Rusch","year":"1991","unstructured":"Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg. 1991;102:1\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"314_CR13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","volume":"117","author":"DJ Sugarbaker","year":"1999","unstructured":"Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54\u201363. discussion 63-5.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"314_CR14","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","volume":"27","author":"M Perrot de","year":"2009","unstructured":"de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:1413\u20138.","journal-title":"J Clin Oncol"},{"key":"314_CR15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002680020021","volume":"25","author":"MT Jaklitsch","year":"2001","unstructured":"Jaklitsch MT, Grondin SC, Sugarbaker DJ. Treatment of malignant mesothelioma. World J Surg. 2001;25:210\u20137.","journal-title":"World J Surg"},{"key":"314_CR16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763\u201372. This United Kingdom trial randomized 50 MPM patients to extra-pleural pneumonectomy (EPP) or best supportive care. They reported no survival benefit to EPP, but had a high mortality rate in the EPP arm. In the USA, EPP is still considered to have a role in surgery for MPM.","journal-title":"Lancet Oncol"},{"key":"314_CR17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/JTO.0b013e31824ab6c5","volume":"7","author":"L Lang-Lazdunski","year":"2012","unstructured":"Lang-Lazdunski L, Bille A, Lal R, et al. Pleurectomy\/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7:737\u201343. This study supports the role of pleurectomy\/decortication in MPM patients.","journal-title":"J Thorac Oncol"},{"key":"314_CR18","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(04)17108-0","volume":"364","author":"T Treasure","year":"2004","unstructured":"Treasure T, Sedrakyan A. Pleural mesothelioma: little evidence, still time to do trials. Lancet. 2004;364:1183\u20135.","journal-title":"Lancet"},{"key":"314_CR19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JTO.0b013e31816fca1b","volume":"3","author":"HF Batirel","year":"2008","unstructured":"Batirel HF, Metintas M, Caglar HB, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol. 2008;3:499\u2013504.","journal-title":"J Thorac Oncol"},{"key":"314_CR20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/annonc\/mdm093","volume":"18","author":"W Weder","year":"2007","unstructured":"Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18:1196\u2013202.","journal-title":"Ann Oncol"},{"key":"314_CR21","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1200\/JCO.2004.10.071","volume":"22","author":"W Weder","year":"2004","unstructured":"Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451\u20137.","journal-title":"J Clin Oncol"},{"key":"314_CR22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/01243894-200605000-00004","volume":"1","author":"RM Flores","year":"2006","unstructured":"Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289\u201395.","journal-title":"J Thorac Oncol"},{"key":"314_CR23","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2007.02.004","volume":"57","author":"F Rea","year":"2007","unstructured":"Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer. 2007;57:89\u201395.","journal-title":"Lung Cancer"},{"key":"314_CR24","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1183\/09031936.00039510","volume":"36","author":"PE Schil Van","year":"2010","unstructured":"Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36:1362\u20139.","journal-title":"Eur Respir J"},{"key":"314_CR25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2407-13-22","volume":"13","author":"R Federico","year":"2013","unstructured":"Federico R, Adolfo F, Giuseppe M, et al. Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013;13:22.","journal-title":"BMC Cancer"},{"key":"314_CR26","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","volume":"6","author":"AS Tsao","year":"2007","unstructured":"Tsao AS, He D, Saigal B, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007;6:1962\u201372.","journal-title":"Mol Cancer Ther"},{"key":"314_CR27","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/JTO.0000000000000177","volume":"9","author":"A Mansfield","year":"2014","unstructured":"Mansfield A, Peikert T, Roden A, et al. Programmed cell death 1 ligand 1 expression and association with survival in mesothelioma. J Thorac Oncol. 2014;9:S7\u2013S52.","journal-title":"J Thorac Oncol"},{"key":"314_CR28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.1991.9.2.313","volume":"9","author":"VW Rusch","year":"1991","unstructured":"Rusch VW, Figlin R, Godwin D, et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol. 1991;9:313\u20139.","journal-title":"J Clin Oncol"},{"key":"314_CR29","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1200\/JCO.1994.12.6.1156","volume":"12","author":"V Rusch","year":"1994","unstructured":"Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy\/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12:1156\u201363.","journal-title":"J Clin Oncol"},{"key":"314_CR30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/030089169608200111","volume":"82","author":"M Colleoni","year":"1996","unstructured":"Colleoni M, Sartori F, Calabro F, et al. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori. 1996;82:53\u20136.","journal-title":"Tumori"},{"key":"314_CR31","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1067\/mtc.2002.125817","volume":"124","author":"TT Lee","year":"2002","unstructured":"Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy\/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"314_CR32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1547-4127(04)00109-4","volume":"14","author":"MY Chang","year":"2004","unstructured":"Chang MY, Sugarbaker DJ. Innovative therapies: intraoperative intracavitary chemotherapy. Thorac Surg Clin. 2004;14:549\u201356.","journal-title":"Thorac Surg Clin"},{"key":"314_CR33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0003-4975(94)91066-9","volume":"58","author":"TW Rice","year":"1994","unstructured":"Rice TW, Adelstein DJ, Kirby TJ, et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1994;58:24\u20139.","journal-title":"Ann Thorac Surg"},{"key":"314_CR34","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2005.00.802","volume":"23","author":"C Lu","year":"2005","unstructured":"Lu C, Perez-Soler R, Piperdi B, et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005;23:3495\u2013501.","journal-title":"J Clin Oncol"},{"key":"314_CR35","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2005.04.6813","volume":"24","author":"WG Richards","year":"2006","unstructured":"Richards WG, Zellos L, Bueno R, et al. Phase I to II study of pleurectomy\/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561\u20137.","journal-title":"J Clin Oncol"},{"key":"314_CR36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1245\/ASO.2003.03.022","volume":"10","author":"S Ruth van","year":"2003","unstructured":"van Ruth S, Baas P, Haas RL, et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol. 2003;10:176\u201382.","journal-title":"Ann Surg Oncol"},{"key":"314_CR37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0022-5223(99)70297-7","volume":"117","author":"GB Ratto","year":"1999","unstructured":"Ratto GB, Civalleri D, Esposito M, et al. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg. 1999;117:759\u201365.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"314_CR38","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","volume":"184","author":"DH Sterman","year":"2011","unstructured":"Sterman DH, Haas A, Moon E, et al. A trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesothelioma. Am J Respir Crit Care Med. 2011;184:1395\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"314_CR39","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-05-0405","volume":"11","author":"DH Sterman","year":"2005","unstructured":"Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase\/ganciclovir suicide gene therapy. Clin Cancer Res. 2005;11:7444\u201353.","journal-title":"Clin Cancer Res"},{"key":"314_CR40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.hoc.2005.09.004","volume":"19","author":"DH Sterman","year":"2005","unstructured":"Sterman DH. Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin N Am. 2005;19:1147\u201373. viii.","journal-title":"Hematol Oncol Clin N Am"},{"key":"314_CR41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1089\/hum.1998.9.7-1083","volume":"9","author":"DH Sterman","year":"1998","unstructured":"Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase\/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083\u201392.","journal-title":"Hum Gene Ther"},{"key":"314_CR42","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-07-0403","volume":"13","author":"DH Sterman","year":"2007","unstructured":"Sterman DH, Recio A, Carroll RG, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res. 2007;13:4456\u201366.","journal-title":"Clin Cancer Res"},{"key":"314_CR43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejcts.2006.11.046","volume":"31","author":"M Lucchi","year":"2007","unstructured":"Lucchi M, Chella A, Melfi F, et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy\/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2007;31:529\u201333. discussion 533-4.","journal-title":"Eur J Cardiothorac Surg"},{"key":"314_CR44","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3","volume":"83","author":"P Astoul","year":"1998","unstructured":"Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer. 1998;83:2099\u2013104.","journal-title":"Cancer"},{"key":"314_CR45","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/1097-0142(19910415)67:8<2033::AID-CNCR2820670804>3.0.CO;2-8","volume":"67","author":"C Boutin","year":"1991","unstructured":"Boutin C, Viallat JR, Van Zandwijk N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer. 1991;67:2033\u20137.","journal-title":"Cancer"},{"key":"314_CR46","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bjc.1995.501","volume":"72","author":"SH Goey","year":"1995","unstructured":"Goey SH, Eggermont AM, Punt CJ, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer. 1995;72:1283\u20138.","journal-title":"Br J Cancer"},{"key":"314_CR47","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0360-3016(03)00287-6","volume":"56","author":"S Yajnik","year":"2003","unstructured":"Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"314_CR48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0003-4975(96)01228-3","volume":"63","author":"EH Baldini","year":"1997","unstructured":"Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63:334\u20138.","journal-title":"Ann Thorac Surg"},{"key":"314_CR49","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0360-3016(02)04151-2","volume":"55","author":"A Ahamad","year":"2003","unstructured":"Ahamad A, Stevens CW, Smythe WR, et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;55:768\u201375.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"314_CR50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/JTO.0b013e31827740f0","volume":"8","author":"DR Gomez","year":"2013","unstructured":"Gomez DR, Hong DS, Allen PK, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8:238\u201345. A review of the patterns of failure post-EPP and IMRT.","journal-title":"J Thorac Oncol"},{"key":"314_CR51","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ijrobp.2007.11.011","volume":"71","author":"EF Miles","year":"2008","unstructured":"Miles EF, Larrier NA, Kelsey CR, et al. Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience. Int J Radiat Oncol Biol Phys. 2008;71:1143\u201350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"314_CR52","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ijrobp.2006.03.012","volume":"65","author":"AM Allen","year":"2006","unstructured":"Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65:640\u20135.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"314_CR53","unstructured":"Komaki R, Liao Z, Liu H, et al: Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma: in regard to Allen et al. (Int J Radiat Oncol Biol Phys 2006;65:640-645). Int J Radiat Oncol Biol Phys 66:1595-6; author reply 1596, 2006"},{"key":"314_CR54","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ijrobp.2005.03.041","volume":"63","author":"V Gupta","year":"2005","unstructured":"Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy\/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"314_CR55","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ijrobp.2011.09.027","volume":"83","author":"KE Rosenzweig","year":"2012","unstructured":"Rosenzweig KE, Zauderer MG, Laser B, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012;83:1278\u201383. Reports on the use of intensity-modulated radiotherapy (IMRT) in MPM patients post-resection.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"314_CR56","doi-asserted-by":"crossref","unstructured":"Rimner A, Spratt DE, Zauderer MG, et al: Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. Int J Radiat Oncol Biol Phys, 2014","DOI":"10.1016\/j.ijrobp.2014.05.032"},{"key":"314_CR57","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1754-9485.2011.02274.x","volume":"55","author":"M Feigen","year":"2011","unstructured":"Feigen M, Lee ST, Lawford C, et al. Establishing locoregional control of malignant pleural mesothelioma using high-dose radiotherapy and (18) F-FDG PET\/CT scan correlation. J Med Imaging Radiat Oncol. 2011;55:320\u201332.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"314_CR58","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2013.10.013","volume":"83","author":"E Minatel","year":"2014","unstructured":"Minatel E, Trovo M, Polesel J, et al. Radical pleurectomy\/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer. 2014;83:78\u201382.","journal-title":"Lung Cancer"},{"key":"314_CR59","doi-asserted-by":"crossref","unstructured":"Chance WW, Rice DC, Allen P, et al: Postoperative hemithoracic intensity-modulated radiation therapy (IMRT) with an optional integrated boost for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. ASTRO abstract, 2014.","DOI":"10.1016\/j.ijrobp.2014.05.1966"},{"key":"314_CR60","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00066-003-1078-0","volume":"179","author":"J Willner","year":"2003","unstructured":"Willner J, Jost A, Baier K, et al. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol. 2003;179:548\u201356.","journal-title":"Strahlenther Onkol"},{"key":"314_CR61","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ijrobp.2010.04.049","volume":"80","author":"JY Chang","year":"2011","unstructured":"Chang JY, Komaki R, Wen HY, et al. Toxicity and patterns of failure of adaptive\/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;80:1350\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"314_CR62","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1002\/cncr.26080","volume":"117","author":"JY Chang","year":"2011","unstructured":"Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117:4707\u201313.","journal-title":"Cancer"},{"key":"314_CR63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semradonc.2010.01.005","volume":"20","author":"JY Chang","year":"2010","unstructured":"Chang JY, Cox JD. Improving radiation conformality in the treatment of non-small cell lung cancer. Semin Radiat Oncol. 2010;20:171\u20137.","journal-title":"Semin Radiat Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0314-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-014-0314-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-014-0314-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T03:25:45Z","timestamp":1598325945000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-014-0314-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,30]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["314"],"URL":"https:\/\/doi.org\/10.1007\/s11864-014-0314-4","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,30]]}}}